Interius BioTherapeutics

Inteirus is thrilled to share that we have a green light to test our first investigational product in the clinic! Our first-in-human Phase 1 clinical trial for INT2104, our first-in-class in vivo targeted gene therapy creating CAR cells for the treatment of B cell malignancies, will start in 4Q24. Thank you to the incredible team of Interians and to our partners, who have made this milestone a reality!

Please join Interius BioTherapeutics' President & CEO, Philip R. Johnson, MD this week in Boston for the 2024 PEGS: The Essential Protein & Antibody Engineering Summit, where he'll be speaking, Thursday, May 16th, at 5:00pm ET on the 'Current Challenges and Opportunities in in vivo Engineering' panel! #PEGSummit #celltherapy #genetherapy #phillybio

Principal Scientists Elaine Youngman presents data on pharmacokinetics and vector shedding for our lead program INT2104 during the Pharmacology Toxicology Studies and Analytics Assay Development session at the annual American Society of Gene & Cell Therapy meeting in Baltimore, MD. The data encompass development studies and a formal GLP toxicology study and support advancement of INT2104 to the clinic as an off the shelf in vivo CAR therapy for B cell malignancies.

Principal Scientist Ronnie Russell delivers an excellent talk in the Emerging Viral Vectors session at the American Society of Gene & Cell Therapy annual meeting describing our platform fusogen for targeted in vivo delivery of gene medicines.

Day 3 of Team Interius making us proud at American Society of Gene & Cell Therapy in Baltimore! Stop by & see some of our poster presentations in person, or view them online: https://lnkd.in/eKiSKA4 Abstract Number 2. In Vivo Generation of Both CAR T Cells and CAR NK Cells Using a CD7 Abstract Number 201. Rational Design of a Detargeted Vesiculovirus Fusogen to Enable Targeted In Vivo Gene Delivery Abstract Number 235. Pharmacokinetics and Vector Shedding in NHPs Following a Single Intravenous Infusion of a CD20-Targeted Engineered Lentiviral Vector Abstract Number 1360. Automating a Lentivirus Infectious Titer Assay (ITA) Abstract Number1361. Evaluation of Residual Host Cell DNA Clearance and Sizing During Production of a Lentiviral Vector Abstract Number 1839. In Vivo Delivery of an Engineered Lentiviral CAR19 Vector for the Treatment of Autoimmune Diseases #asgct #asgct2024 #phillybio

This morning Interius BioTherapeutics was honored to present our data during the Presidential Symposium at the 27th Annual American Society of Gene & Cell Therapy meeting. Our abstract was one of only three selected from the thousands submitted for this important honor. We are proud of the team and the team effort that put us on that stage.

We have two exciting opportunities now available to join the Discovery Group at Interius BioTherapeutics: one for a Scientist/Sr. Scientist and another for a Research Assistant/Associate. Come join our fantastic voyage as we continue to develop new ways to engineer cells inside the human body!   Scientist/Sr. Scientist: https://lnkd.in/g2aEdhYg   Research Assistant/Associate: https://lnkd.in/gaRgVD4E   Please feel free to reach out if you are interested in applying or forward along to others who may be good candidates.

Interius BioTherapeutics is excited to share data on our in vivo CAR programs in oncology and autoimmunity at the forthcoming American Society of Gene & Cell Therapy Annual Meeting on May 7-11 in Baltimore, MD! Come see our presentations and meet us at the conference!

Congratulations to our one and only Patricia Freire Greeley, SHRM-SCP for being selected a finalist for the Delaware Valley HR Person of the Year Awards! Interius BioTherapeutics has already won for having you on our team, Trish!

What a wonderful series initiated by Pennovation Works! At the conclusion of #WomensHistoryMonth, we are delighted and incredibly proud of our two Interians who were recognized, Léolène J. Carrington, Ph.D. and Tiffany Scott. Read their inspirational words and learn more about the Pennovation campus here: https://lnkd.in/gE2EvEmU